CN108704083A - Application of the gout granules in treating diabetes - Google Patents
Application of the gout granules in treating diabetes Download PDFInfo
- Publication number
- CN108704083A CN108704083A CN201810768011.2A CN201810768011A CN108704083A CN 108704083 A CN108704083 A CN 108704083A CN 201810768011 A CN201810768011 A CN 201810768011A CN 108704083 A CN108704083 A CN 108704083A
- Authority
- CN
- China
- Prior art keywords
- group
- diabetes
- rat
- drug
- gout granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 38
- 201000005569 Gout Diseases 0.000 title claims abstract description 33
- 239000008187 granular material Substances 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 29
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 230000036541 health Effects 0.000 claims abstract description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 102000004877 Insulin Human genes 0.000 claims abstract description 5
- 108090001061 Insulin Proteins 0.000 claims abstract description 5
- 229940125396 insulin Drugs 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 230000006378 damage Effects 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 3
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 49
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 20
- 239000002689 soil Substances 0.000 description 18
- 238000001514 detection method Methods 0.000 description 11
- 229960005095 pioglitazone Drugs 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000003907 kidney function Effects 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- 108091008611 Protein Kinase B Proteins 0.000 description 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000005084 renal tissue Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 241000235503 Glomus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000037308 hair color Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000000512 proximal kidney tubule Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 description 1
- 244000307697 Agrimonia eupatoria Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241001645380 Bassia scoparia Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000601164 Clematis orientalis Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 240000004638 Dendrobium nobile Species 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 244000062241 Kaempferia galanga Species 0.000 description 1
- 235000013421 Kaempferia galanga Nutrition 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 241000362909 Smilax <beetle> Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001533104 Tribulus terrestris Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000000125 common agrimony Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides application of the gout granules in treating diabetes, especially preparing the purposes in preventing or treating the drug or health products of diabetes B, wherein the preparation prevents or the drug for the treatment of diabetes B is the drug for improving patient insulin's sensibility.Since the gout granules belong to Chinese medicine, relative to Western medicine, the damage smaller of stomach and liver to patient is more suitable for taking for a long time.
Description
Technical field
The invention belongs to biomedicine fields, and in particular to a kind of gout granules and its application.
Background technology
It is also known as diabete in diabetes Chinese medicine, is clinically mainly shown as diuresis, more drinks, polyphagia shape, is a kind of tight
The chronic disease of human health is endangered again, and incidence is higher and higher.It is old with world population with the improvement of people ' s living standards
The incidence of the quickening in age, diabetes significantly increases.Epidemiologic data is shown within 1980, and the illness rate of China's diabetes is about
It is 0.67%, and by 2008, through investigation and analysis, estimation China reached 9.7% more than 20 years old adult's diabetes prevalence.
Based on the population base in China 1,300,000,000, in addition the illness rate that diabetes are so high, 30 years short, China or have become sugared in the world
Sick first big country of urine.
It is that the third-largest Health Killer after malignant tumour, angiocardiopathy just seriously threatens China that diabetes, which are known as,
National health.Researches show that China there are about 20,000,000 or more diabetic, the various complication caused have become after
After cardiovascular and cerebrovascular disease and malignant tumour, the third position killer of people's life is threatened.Diabetes (DM) are one kind due to pancreas islet
Element secretion absolutely or relative deficiency, using hyperglycemia as the endocrine metabolism disease of main feature caused by carbohydrate metabolism disturbance.
It is analyzed from pathology angle, diabetes are broadly divided into insulin-dependent (1 type) and non-insulin-depending type (2 type), wherein 2 types
Diabetes are most commonly seen (accounting for 90% or more), and age of onset increasingly tends to rejuvenation, are currently to endanger human health
Common disease, frequently-occurring disease.
The original name of diabetes B is called Adult Onset's patients with type Ⅰ DM, and clinically often 35 years old or more a middle-aged person is more
Hair.2 patients with type Ⅰ DM are that clinically a kind of type of most commonly seen diabetes clinically accounts for all diabetics at present
90% or more.The clinical onset reason of diabetes B patient is more in pathogenic factor, factor the most main be heredity because
Element, environmental factor, ethnic factor and age factor.Wherein, fat, high fever diet and physical exertion deficiency are to lead to 2 types
The main reason for diabetes.Diabetes B patient is during clinical onset, it may appear that many symptoms, such as patient's meeting
There is the case where insulin sensitivity declines, while the insulin in blood samples of patients also will present out a kind of horizontal feelings promoted
Condition.
The research of Chinese medicine hypoglycemic drug is received significant attention in recent years, many Chinese medicines were once individually clinically used for
Hyperglycemia is treated, such as cordyceps sinensis, ginseng, galangal, Radix Astragali, Fructus Corni, the fruit of Chinese wolfberry, sealwort, the stem of noble dendrobium, Schisandra chinensis, rheum officinale, Huang
Company, rhizoma atractylodis, pueraria lobata, cape jasmine, mulberry leaf, puncture vine, giant knotweed, corn stigma, Ramulus euonymi, hairyvein agrimony, fruit of summer cypress etc..So far clinically
Diabetes can be cured completely there has been no a kind of drug, and Chinese medicine has many advantages, such as mild property, small toxicity, weak to gastric irritation, by people
Be widely recognized as, have a bright future long-range.
Invention content
The present invention is to carry out in order to solve the above problem, and it is an object of the present invention to provide a kind of gout granules prevent or control preparing
The drug for treating diabetes or the purposes in health products.Especially in the drug or health products for preparing prevention or treatment diabetes B
Purposes.Wherein, the drug for preparing prevention or treatment diabetes B is the drug for improving patient insulin's sensibility.
The details of various aspects of the present invention will be able to detailed description in subsequent chapters and sections.By hereafter and claim
Description, the features of the present invention, purpose and advantage will become apparent from.
The effect of invention
By subsequent experimental results it is found that the effect of gout granules tool is significantly reduced blood sugar concentration, can use
In the drug for preparing treatment diabetes.Further, since the gout granules belong to Chinese medicine, relative to Western medicine, stomach to patient and
The damage smaller of liver, is more suitable for taking for a long time.
Description of the drawings
Fig. 1 is experimental design and the flow chart of the present invention；
Fig. 2 is rat kidney histopathology morphological observation testing result of the present invention；
Fig. 3 is PCR program settings interface；
Fig. 4 is the Real time PCR testing results that each gene of rat kidney tissue is administered.
Specific implementation mode
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.Reagent and raw material used in the following example can be bought by commercial sources to be obtained
.In the following examples, the experimental methods for specific conditions are not specified, usually according to normal condition or according to proposed by manufacturer
Condition.Unless otherwise defined, all professional and scientific terms used in text and meaning known to one skilled in the art
Justice is identical.In addition, any method and material similar or impartial to described content can be applied to the method for the present invention.Wen Zhong
The preferred implement methods and materials are for illustrative purposes only.
The feature that the features described above or embodiment that the present invention mentions are mentioned can be in any combination.Patent specification is taken off
All features shown can be used in combination with any composition form, and each feature disclosed in specification any can provide phase
The alternative characteristics substitution of same, impartial or similar purpose.Therefore it is only impartial or similar except having special instruction, revealed feature
The general example of feature.
The formula of 1 gout granules of embodiment
Specifically, the purposes the present invention provides gout granules in the drug or health products for the treatment of diabetes, described
Gout granules formula is as follows：Smilax, silkworm excrement, root of Chinese clematis, Bi Collettiis, gypsum, plantain seed.
2 gout granules of embodiment treat the pharmacodynamic study of diabetes
Experimental design in the present embodiment is as shown in the flow chart in Fig. 1.
1. animal feed
High-sugar-fat-diet is added by 66.5% basestocks, 2.5% cholesterol, 1% sodium taurocholate, 20% sucrose and 10% lard
Water mixing is done into strips, is placed in thermostatic drying chamber (80-85) DEG C, 3-4 hours.The nutritional ingredient of basestocks meets national standard
《GB149243-2001 experimental animal rat mixed feeds》Trophic level.
2. the foundation of rat diabetes model
Each group rat (except Normal group) rat is raised with high-sugar-fat-diet 5 weeks, after the obese model for causing rat,
Fasting 12h surveys each group rat limosis tail vein blood glucose.Rat is pressed per the intraperitoneal disposable injection streptozotocin of kg weight
(STZ)40mg.STZ is made into 2% solution with sodium citrate buffer solution (0.1mol/L pH4.5) before use, while control group is noted
Penetrate the same dose of citrate buffer solutions, Routine Test Lab forage feed, normal water.1 week detection each group rat serum after injection
Sugar, blood glucose are set to diabetes rat more than 16.65mmol/L person.
3. experiment packet
As shown in Figure 1, this experiment is divided into agent in control group, model group, gout granules low dose therapy group, gout granules
Measure treatment group, gout granules high-dose therapy group and positive drug group (Pioglitazone piece 1.5mg/kg dosage).In model success
Start within the 4th day, give gout granules low dose group, middle dose group and high dose group respectively by by adult human dose with body surface face
Gout granules solution gavage, positive drug group (Pioglitazone piece 1.5mg/kg dosage), model group and sky are given in product scaling method conversion
White group is only with appropriate physiological saline gavage.Medicine 1 time a day, is treated 28 days altogether.Entire Therapy lasted 10 weeks.Then to each
Organize influence, weight, hepatic and renal function, SOD and the MDA, renal tissues pathology morphological observation and Real time PCR of general symptom
Detection.
4. the influence of the general symptom of rat
The general state of the record rat of same time of (0,1,2,3,4 week), including experimental rat weekly after administration
The state of mind, hair color, weight, food ration, urine volume, to reaction, the survival rate of environmental stimuli situations such as.
4.1 result
Normal rats hair color gloss, activity is normal, is quick on the draw to extraneous environmental stimulus, diabetic model group Hair of Rat
Send out in disorder, hair color is withered, matt.During experiment, the fur gloss of administration group rat makes moderate progress.It is big that metabolic cage collects each group
Mouse hour food ration, amount of drinking water and urine volume, the symptom of the more drinks of as a result display model group rat appearance, mostly food, diuresis, with normal group
Comparing difference has statistical significance (P<0.05).
As shown in table 1, after being administered 4 weeks, food ration, amount of drinking water, the urine volume of the rat of gout granules group have compared with model group
It is reduced, group difference has statistical significance (P<0.05).Compared with model group, Pioglitazone group rat urine volume substantially reduces
(P<0.05), food ration is not improved (P> with amount of drinking water;0.05).
1 each group rat food ration of table, amount of drinking water and urine volume statistics
| Group | Food ration | Amount of drinking water | Urine volume |
| Normal group | 25.43 soil 5.42 | 28.42 soil 7.94 | 13.92 soil 5.13 |
| Model group | 39.53 soil 6.07** | 106.09 soil 21.59** | 66.07 soil 12.01** |
| Low dose group | 36.84 soil 6.32** | 83.86 soil 9.89**## | 63.47 soil 9.42** |
| Middle dose group | 35.14 soil 6.49**# | 82.02 soil 9.32**## | 58.60 soil 8.92**# |
| High dose group | 33.82 soil 7.16**## | 74.09 soil 4.33**## | 55.06 soil 4.81**## |
| Pioglitazone group | 28.53 soil 6.17*## | 61.05 soil 5.49**## | 50.80 soil 14.21**## |
Note：Compared with normal group, * * P<0.01, compared with model group, #P<0.05, ##P<0.01.
5. influence of the gout granules to rat body weight
During experiment, normal rats weight gradually increases, other group of rat body weight increasess slowly, compared with normal group,
The phenomenon that reducing is presented in diabetes rat body weight.The weight of model group rats is substantially less than normal group of (P<, and model 0.05)
Weight is remarkably decreased compared with the last week when group rat the 4th week.Pioglitazone group continues slowly to increase with gout granules group rat body weight.
Gout granules group rat body weight is higher than model group rats at the 4th week, and difference has statistical significance (P<0.05) it, is specifically shown in Table
2：
The changes of weight result result of the different group rats of table 2
Note：Compared with normal group, * * P<0.01.
6. influence of the gout granules to rat hepatic and renal function
6.1 material
Healthy male SD rat is chosen, weight 200g ± 20g, is carried totally by Shanghai Si Laike Experimental Animal Centers by 105
For animal feeding environment：Shanghai Univ. of Traditional Chinese Medicine's cleaning grade laboratory rearing, 20-25 DEG C of temperature, humidity 40%-70%, noise
60 decibels of <, 10-20 times/h of rate of ventilation, work illumination L/D=12h/12h.All animals buy rear adaptability sub-cage rearing back
It 1 week, has no adverse reaction, diet, the normal person of drinking-water are included in experiment.Conventional adaptation nursing after according to Normal group,
Model group, gout granules (high, medium and low dosage) treatment group and positive drug group (Pioglitazone piece 1.5mg/kg dosage), each 10
Only, the foundation of rat diabetes model is prepared, after modeling success, low dose group, middle dose group and height are pressed by gout granules treatment group
Dosage group gives 4.375g/kg, 8.75g/kg and 17.5g/kg weight/d respectively, 2 times/d, daily gastric infusion；Pyrrole lattice row simultaneously
Ketone group presses daily 1.5mg/kg weight/d, and 1 time/d gives to treat, remaining control group and model group are to wait physiological saline of capacity to fill
Stomach puts to death materials after continuous 28d.
Experimental drug：Gout granules (are prepared) by embodiment 1
6.2 method
The measurement of the influence of rat hepatic and renal function：Automatic clinical chemistry analyzer carries out the detection of liver function, kidney function.
6.3 result
Normal group is compared, the horizontal apparent increase (P< of model group rats ALT, Cr;0.01), illustrate joint STZ inductions high in fat
There is the damage of hepatic and renal function to a certain degree in rat, especially liver function damage is apparent.After pharmaceutical intervention 4 weeks, Pioglitazone group
And high dose gout granules group rat ALT is obviously improved, compared with model group, difference has statistical significance (P<0.05).Its
Cr, BUN, AST level of his administration group rat are compared with model group, no significant difference (P>0.05), illustrate gout
Grain is intervened 4 weeks, can be alleviated liver function damage caused by high fat diet, is not improved to renal function, but also without aggravating liver
The damage of renal function illustrates that gout granules medication is comparatively safe, is specifically shown in Table 3：
ALT, AST, BUN and Cr of the different group rats of table 3 are horizontal
Note：Compared with normal group, * * P<0.01.
7. administration before and treatment 28 days after rat blood serum SOD and MDA content detection result
7.1 material
Behind 4 weeks for the treatment of, pass through Culling heart blood (using clinically common vacuum blood collection tube) 3mL, centrifuge
3000rpm, 4 DEG C of centrifugation 15min detach serum, and -80C is preserved.
7.2 method
Rat blood serum SOD and MDA content detection：Automatic clinical chemistry analyzer carries out SOD and MDA content detections.
7.3 result
Compared with normal group, model group rats Content of MDA is significantly higher than normal group of (P<0.01), SOD activity is apparent
Less than normal group (P<0.01).Compared with model group, Pioglitazone group rat SOD vigor significantly improves, and MDA contents obviously drop
Low, difference has statistical significance (P<0.01)；Significant difference (P> is not present with model group in middle high dose group;0.05), have
Body is shown in Table 4.
Rat blood serum SOD and MDA content detection is administered in table 4
Note：Compared with normal group, * * P<0.01, compared with model group, #P<0.05, ##P<0.01.
8. rat kidney histopathology morphological observation testing result is administered
Observation detection is carried out to the renal tissues pathology form of each group rat using HE dyeing, the results are shown in Figure 2.Control
Group：Glomerulus structure, form, normal in size, glomus, proximal tubule and distal tubule normal with the ratio of glomerulus blister cavities
Tube wall thin and thick, tube chamber normal in size.Model group：Glomerulus structure, form, size are abnormal, the apparent loose, mesentery of glomerulus
Matrix increases；Glomus atrophy, kidney balloon cavity become larger, the tube wall thin and thick of proximal tubule and distal tubule is irregular, tube chamber size not
One, swelling has a large amount of inflammatory cell infiltration.Low dose group glomerulus structure is similar with model group structure.Middle dose group kidney is small
Spherical structure slightly improves.High dose group glomerulus and renal tubule structure are obviously improved, Pioglitazone group glomerulus structure, form,
Size is normal, and glomus is full, glomerulus blister cavities still has slight change, and ratio is normal, and proximal tubule and distal end are small
The tube wall of pipe is thin, tube chamber size is normal, and swelling mitigates, still visible a small amount of inflammatory cell.
9. each gene Real time PCR detections of rat kidney tissue
9.1 experiment reagent：
Reagent summarizes needed for 5 Real time PCR of table
9.2 experimental method
The extraction and identification of 1.Total RNA
1) take appropriate tissue sample that Trizol is added, tissue refiner is homogenized 3min；12,000g 4 DEG C of centrifugation 15min, take
Supernatant.
2) 1/5 volume of chloroform is added, acutely vibrates 15s, waits for the fully emulsified no phase separation phenomenon of solution, be stored at room temperature 5min；
3) 12,000g, 4 DEG C of centrifugation 15min；
4) centrifuge tube is carefully taken out, Aspirate supernatant is transferred in another RNase free EP pipes；
5) isometric isopropanol is added, turns upside down after mixing well, is stored at room temperature 10min；
6) 12,000g, 4 DEG C of centrifugation 10min, discard supernatant；
7) 75% ethyl alcohol l mL washings, 12,000g 4 DEG C of centrifugation 5min, carefully discard ethyl alcohol；
8) 20 μ L sterilizing DEPC water dissolutions precipitations are added in drying at room temperature 2-3min, and EP bottom of the tube is flicked to complete with finger tip
Fully dissolved.
9) RNA sample concentration is measured.OD260/OD280=1.91, the RNA purity of extraction is high, the remnants of no protein and DNA.
2.cDNA is synthesized
1) mixed liquor is prepared in 0.2mL RNase free EP pipes, operated on ice.
2) reverse transcription reaction
6 reverse transcription reaction system of table
3) 37 DEG C of 15min, 85 DEG C of 5sec.10 μ L ddH are added in obtained cDNA2O dilutions are spare.It can be directly used for 2nd-
The synthesis of Strand cDNA or PCR amplification, -20 DEG C of preservations.The recommendation maximum usage amount of cDNA is 1 μ L when PCR amplification.
3. quantitative PCR reacts
1) primer sequence and analysis condition designed is as follows：
7 primer information of table
2) PCR reaction mixtures are prepared in PCR pipe, are operated on ice.
8 real-time PCR reaction systems of table
3) mixing, each sample do 3 repetitions and compare.
4) PCR programs are set
Program setting is carried out as shown in Figure 3.
Stage 1：Pre-degeneration
Reps：1
95℃30s；
Stage 2：PCR reacts
Reps：40
95℃5s
60 DEG C of 30~40s；
Stage 3：
95℃15s
60℃1m
95℃15s；
Cycle 40
5) machine augmentation detection on, utilizes 2–ΔΔCtCalculate relative expression quantity.
9.3 experimental result
AKT, PI3K, mTOR, PTEN expression quantity of 9 each group rat of table
*P<0.05VS control groups, * * P<0.01VS control groups
As shown in Figure 4 is directed to each gene expression amount Real time PCR detection datas, and AKT, PI3K and mTOR are normal
The expression quantity of group is substantially less than other groups (P<0.05), in addition the expression quantity of AKT, PI3K and mTOR of model group are significantly higher than it
His group.The expression quantity for increasing AKT, PI3K and mTOR with drug concentration reduces successively, and high dose group and Pioglitazone group effect
Fruit is best.The gene expression amount of PTEN and other indexs are just the opposite.Illustrate that gout granules have certain therapeutic effect.
The basic principles, main features and advantages of the present invention have been shown and described above.The technology of the industry
Personnel are it should be appreciated that the present invention is not limited to the above embodiments, and the above embodiments and description only describe this
The principle of invention, various changes and improvements may be made to the invention without departing from the spirit and scope of the present invention, these changes
Change and improvement all fall within the protetion scope of the claimed invention.The claimed scope of the invention by appended claims and its
Equivalent defines.
Sequence table
<110>Zhu Wanhua
<120>A kind of gout granules and its application in treating diabetes
<130>Specification
<160> 10
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 1
ttatagaggg atacaagggg gag 23
<210> 2
<211> 23
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 2
cgccgtctga ttatcttgat gag 23
<210> 3
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 3
caggaccacg agaagctgtt 20
<210> 4
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 4
gatctccttg gcatcctcgg 20
<210> 5
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 5
ggagaaccag ccctaagctc 20
<210> 6
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 6
cagtgatggg gttttgcagc 20
<210> 7
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 7
atgcccaact tctccgacag 20
<210> 8
<211> 21
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 8
aggacttccg gtactcccct c 21
<210> 9
<211> 21
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 9
aggtcggtgt gaacggattt g 21
<210> 10
<211> 23
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 10
tgtagaccat gtagttgagg tca 23
Claims (3)
1. gout granules are preparing the purposes in preventing or treating the drug or health products of diabetes.
2. gout granules are preparing the purposes in preventing or treating the drug or health products of diabetes B.
3. gout granules according to claim 2 are in the drug or health products for preparing prevention or treatment diabetes B
Purposes, it is characterised in that：
Wherein, the drug for preparing prevention or treating diabetes B is the drug for improving patient insulin's sensibility.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810768011.2A CN108704083A (en) | 2018-07-13 | 2018-07-13 | Application of the gout granules in treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810768011.2A CN108704083A (en) | 2018-07-13 | 2018-07-13 | Application of the gout granules in treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108704083A true CN108704083A (en) | 2018-10-26 |
Family
ID=63875000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810768011.2A Withdrawn CN108704083A (en) | 2018-07-13 | 2018-07-13 | Application of the gout granules in treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108704083A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895522A (en) * | 2006-06-26 | 2007-01-17 | 朱良春 | Gout granules |
-
2018
- 2018-07-13 CN CN201810768011.2A patent/CN108704083A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895522A (en) * | 2006-06-26 | 2007-01-17 | 朱良春 | Gout granules |
Non-Patent Citations (1)
| Title |
|---|
| 朱慎勇: ""针药结合治疗原发性痛风58 例分析"", 《中医药临床杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101878906B (en) | Health care food with auxiliary hyperglycemic function and preparation method thereof | |
| CN103494197A (en) | Health-care food with functions of enhancing immunity and assisting to reduce blood sugar and preparation method of food | |
| CN102845749A (en) | Health-care composition capable of improving sleep and aiding in improving memory | |
| CN101987169A (en) | Composition comprising an extract of herbal combination thereof for preventing and treating diabetes mellitus | |
| CN108392519A (en) | A kind of hypoglycemic composition and its preparation and application | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| CN102935116A (en) | Pharmaceutical compositions or health care product having blood sugar reduction effect | |
| CN105725187B (en) | A kind of hypoglycemic composition and its purposes for being used to prepare food and health food | |
| CN102578668B (en) | Beverage for assisting in reducing blood sugar | |
| CN108704083A (en) | Application of the gout granules in treating diabetes | |
| CN109771457A (en) | Purposes of the russule extract in the preparation that preparation treatment and/or prevention high fat diet cause hepatic injury related disease | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN107073060A (en) | Chinese cassia tree and the water extract of the Radix Astragali | |
| CN113041300B (en) | Prescription for treating diabetes and its application | |
| CN113499366B (en) | Composition with function of reducing blood sugar and blood fat simultaneously and preparation method thereof | |
| CN108165499A (en) | A kind of culture medium of Hericium erinaceus, Chinese yam bioconversion mycelium, the mycelial extract of Chinese yam bioconversion and application thereof | |
| CN103445176A (en) | Health food for enhancing immunity and preparation method thereof | |
| CN103920140A (en) | Compound preparation for reducing blood glucose, body weight and fat for human | |
| CN104173734B (en) | A kind of pharmaceutical composition for treating IGR and preparation method thereof | |
| CN103585583B (en) | Traditional Chinese medicine composition for treating hepatic calculus and application thereof | |
| CN110840996A (en) | Traditional Chinese medicine formula, method, preparation and application for treating qi-yin deficiency metabolic syndrome | |
| CN109771454A (en) | Purposes of the birch young pilose antler extract in the preparation that preparation treatment and/or prevention high fat diet cause hepatic injury related disease | |
| CN106309546A (en) | Extract for treating diabetic nephropathy | |
| CN110507759A (en) | A kind of three yellow Chinese herbal preparation of particles and preparation method thereof with control hyperglycemia | |
| CN113171424B (en) | Traditional Chinese veterinary medicine preparation for treating liver lipid deposition of dogs and cats and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181026 |